LANTERN PHARMA INC LTRN
ASignal's systematic analysis rates LTRN as Bearish.
Reflects the latest available analysis · analyzed Nov 10, 2026
The case on LTRN
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Positive free cash flow trend indicated by improving financial health score
- Current ratio of 1.96x suggests short-term liquidity strength
- RSI at 33 indicates potential oversold condition, which may signal downside protection
- Negative MACD and price momentum indicating ongoing downtrend
- Price trading significantly below SMA20 and SMA50, signaling strong bearish trend
- Negative return on equity (-400.92%) and negative margins across all levels
- High beta of 2.46x indicating extreme volatility and market sensitivity
- Negative enterprise value to EBITDA and price-to-book ratio suggesting valuation concerns
- No news coverage or Reddit mentions, indicating lack of market interest or visibility
See the full verdict on LTRN
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes LTRN
Most investors never get a second opinion, let alone several. ASignal runs LTRN past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.